AIP
NRIX icon

Ameritas Investment Partners’s Nurix Therapeutics NRIX Stock Holding History

Ameritas Investment Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$126K Hold
8,136
– – ﹤0.01% 1544
2025
Q4 		$154K Buy
8,136
+1,838
+29% +$26.4K ﹤0.01% 1419
2025
Q3 		$58.2K Sell
6,298
-1,047
-14% -$10.9K ﹤0.01% 2025
2025
Q2 		$83.7K Hold
7,345
– – ﹤0.01% 1871
2025
Q1 		$87.3K Hold
7,345
– – ﹤0.01% 1796
2024
Q4 		$138K Buy
7,345
+877
+14% +$20.1K ﹤0.01% 1561
2024
Q3 		$145K Buy
6,468
+539
+9% +$12.2K ﹤0.01% 1542
2024
Q2 		$124K Buy
5,929
+1,308
+28% +$20.4K ﹤0.01% 1596
2024
Q1 		$67.9K Hold
4,621
– – ﹤0.01% 1969
2023
Q4 		$47.7K Hold
4,621
– – ﹤0.01% 2195
2023
Q3 		$36.3K Buy
4,621
+1,296
+39% +$11.8K ﹤0.01% 2267
2023
Q2 		$33.2K Hold
3,325
– – ﹤0.01% 2281
2023
Q1 		$29.5K Hold
3,325
– – ﹤0.01% 2283
2022
Q4 		$42.1K Hold
3,325
– – ﹤0.01% 2182
2022
Q3 		$43K Hold
3,325
– – ﹤0.01% 2094
2022
Q2 		$42K Buy
3,325
+869
+35% +$9.85K ﹤0.01% 2103
2022
Q1 		$34K Hold
2,456
– – ﹤0.01% 2282
2021
Q4 		$71K Hold
2,456
– – ﹤0.01% 1906
2021
Q3 		$74K Hold
2,456
– – ﹤0.01% 1880
2021
Q2 		$65K Buy
2,456
+509
+26% +$14.9K ﹤0.01% 2009
2021
Q1 		$61K Buy
1,947
+1,001
+106% +$37.9K ﹤0.01% 1964
2020
Q4 		$31K Hold
946
– – ﹤0.01% 2257
2020
Q3 		$33K Buy
+946
New +$23.8K ﹤0.01% 2095

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Ameritas Investment Partners's NRIX Position: Q1 2026 in Review

Ameritas Investment Partners held its Nurix Therapeutics (NRIX) position steady in Q1 2026 at 8,136 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

Ameritas Investment Partners first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $154K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Ameritas Investment Partners held 8,136 shares of Nurix Therapeutics worth $126K as of Q1 2026.
  • Ameritas Investment Partners left its Nurix Therapeutics share count unchanged in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1544 holding.
  • Ameritas Investment Partners first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Ameritas Investment Partners's Nurix Therapeutics position peaked at $154K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.